Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets
MedComm · 2026-02 · 7 (2)
DOI: 10.1002/mco2.70604 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 05.02.2026. Verfasst von Jingyuan Wen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Transplantation Surgery Department of General Surgery Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing U…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 322 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Bone metastasis (BoMet) is a common complication in various cancers. Approximately 20–30% of patients with cancer develop BoMet, which is most frequently associated with solid tumors, such as breast, prostate, and lung cancers. BoMet can lead to skeletal‐related events such as fractures, bone pain, and hypercalcemia, negatively affecting the patient's quality of life and markedly shortening overall survival. The development of BoMet is a complex, multistep process driven by dynamic interactions between tumor cells and the bone microenvironment. The bone microenvironment provides a supportive niche for disseminated tumor cells, where intricate signaling networks and stromal interactions regulate the initiation, dormancy, reactivation, and progression of BoMet. Although current bone‐targeted therapies can reduce the incidence of these complications, the clinical outcomes for patients with BoMet remain poor. Therefore, elucidating the molecular mechanisms governing these interactions is essential for identifying new therapeutic strategies. This review systematically explores the molecular drivers of BoMet progression, dynamic interactions within the metastatic niche, available preclinical models, established treatment modalities, and emerging therapeutic approaches. As fundamental research continues to advance toward clinical translation, the outlook for patients with BoMet is expected to improve significantly.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepatobiliary and Transplantation Surgery Department of General Surgery Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing China.
- Department of Breast Surgery Department of General Surgery Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School Nanjing China.
- Department of Urology Fudan University Shanghai Cancer Center Shanghai China.
- Division of Hepato-Pancreato-Biliary Surgery Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
- Clinical Medical Research Center for Hepatic Surgery of Hubei Province Wuhan China.
- Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases Wuhan China.
ORCID-Profile: Jingyuan Wen, Zhao Huang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wen, J., Li, B., Wang, S., Yao, Y., Huang, Z., & Yu, D. (2026). Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets. MedComm, 7(2). https://doi.org/10.1002/mco2.70604
Vancouver
Wen J, Li B, Wang S, Yao Y, Huang Z, Yu D. Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets. MedComm. 2026;7(2). doi:10.1002/mco2.70604
BibTeX
@article{Wen2026,
author = {Wen, Jingyuan and Li, Binghua and Wang, Shengjia and Yao, Yongzhong and Huang, Zhao and Yu, Decai},
title = {Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets},
journal = {MedComm},
year = {2026},
volume = {7},
number = {2},
doi = {10.1002/mco2.70604}
}
EUVIMED